Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2020 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study).
Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139. doi: 10.1093/ofid/ofaa139. eCollection 2020 May.
Open Forum Infect Dis. 2020.
PMID: 32462046
Free PMC article.
BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. METHODS: A multicenter retros …
BACKGROUND: Few data are reported in the literature about the outcome of patients with severe extended-spectrum beta-lactamase-producing Ent …
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, Menichetti F, Mastroianni CM, Tumbarello M, Grossi P, Artioli S, Carannante N, Cipriani L, Coletto D, Russo A, Digaetano M, Losito AR, Peghin M, Capone A, Nicolè S, Vena A; CEFTABUSE Study Group.
Bassetti M, et al.
Int J Antimicrob Agents. 2019 Apr;53(4):408-415. doi: 10.1016/j.ijantimicag.2018.11.001. Epub 2018 Nov 8.
Int J Antimicrob Agents. 2019.
PMID: 30415002
Free article.
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 hospitals in Italy (June 2016-March 2018). ...
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infectio …
Item in Clipboard
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa.
Vena A, Giacobbe DR, Mussini C, Cattelan A, Bassetti M; Ceftabuse Study Group.
Vena A, et al.
Clin Infect Dis. 2020 Oct 23;71(7):1799-1801. doi: 10.1093/cid/ciaa003.
Clin Infect Dis. 2020.
PMID: 31904819
No abstract available.
Item in Clipboard
Cite
Cite